{"nctId":"NCT01240746","briefTitle":"Study of Quadrivalent Influenza Vaccine Among Children","startDateStruct":{"date":"2010-11"},"conditions":["Influenza"],"count":4363,"armGroups":[{"label":"Group 1: Licensed 2010-2011 TIV","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative"]},{"label":"Group 2: Investigational TIV","type":"EXPERIMENTAL","interventionNames":["Biological: Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative"]},{"label":"Group 3: Investigational QIV","type":"EXPERIMENTAL","interventionNames":["Biological: Quadrivalent Influenza Vaccine, No Preservative"]}],"interventions":[{"name":"Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative","otherNames":["Fluzone®"]},{"name":"Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative","otherNames":[]},{"name":"Quadrivalent Influenza Vaccine, No Preservative","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is 6 months to \\< 9 years of age on the day of inclusion.\n* Parent/guardian is willing and able to attend scheduled visits and to comply with the study procedures during the entire duration of the study.\n* Subject is in reasonably good health as assessed by the Investigator.\n* Informed consent is granted by the parent(s) or other legally acceptable representative; assent by subjects 7 to \\< 9 years of age.\n* For subjects 6 months to \\< 24 months of age, born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg (5.5 lbs).\n\nExclusion Criteria:\n\n* History of allergy to egg proteins or any constituents of the vaccine.\n* History of serious adverse reaction to any influenza vaccine.\n* Any vaccination scheduled between Visit 1 and Visit 2 (or Visit 1 and Visit 3 for those requiring two doses).\n* Receipt of any vaccine in the 4 weeks preceding the first study vaccination.\n* Participation in another interventional clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first study vaccination or during the course of the study.\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.\n* Any condition that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine.\n* Personal history of Guillain-Barré syndrome.\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* Personal or immediate family history of congenital immune deficiency.\n* Personal developmental delay, neurologic disorder, or seizure disorder.\n* Any chronic illness that, in the opinion of the Investigator, is not well controlled and may interfere with trial conduct or completion, or with assessment of adverse events.\n* Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C.\n* Receipt of blood or blood-derived products (including immunoglobulin therapy) in the past 3 months, which might interfere with assessment of the immune response.\n* Employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members of the employees or the Investigator.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"8 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants","description":"Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1096","spread":null},{"groupId":"OG002","value":"1124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"828","spread":null},{"groupId":"OG002","value":"822","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines With Corresponding B Strain in All Participants","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.\n\nSeroconversion was defined as either a pre-vaccination HAI titer \\<1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥four-fold increase in post-vaccination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"355","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"1677","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"383","spread":null},{"groupId":"OG002","value":"1543","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines With Corresponding B Strain in All Participants","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"86.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"58.3","spread":null},{"groupId":"OG002","value":"61.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines Without Corresponding B Strain in All Participants","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"19.5","spread":null},{"groupId":"OG002","value":"86.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"61.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.\n\nSeroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"291","spread":null},{"groupId":"OG001","value":"305","spread":null},{"groupId":"OG002","value":"1159","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"573","spread":null},{"groupId":"OG001","value":"585","spread":null},{"groupId":"OG002","value":"2305","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"248","spread":null},{"groupId":"OG001","value":"241","spread":null},{"groupId":"OG002","value":"946","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"575","spread":null},{"groupId":"OG001","value":"593","spread":null},{"groupId":"OG002","value":"2326","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"261","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"418","spread":null},{"groupId":"OG001","value":"202","spread":null},{"groupId":"OG002","value":"1838","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"416","spread":null},{"groupId":"OG002","value":"1674","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroconversion Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.\n\nSeroconversion was defined as either a pre vaccination HAI titer \\<1:10 and a post vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a four-fold increase in post-vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"541","spread":null},{"groupId":"OG001","value":"535","spread":null},{"groupId":"OG002","value":"2135","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"477","spread":null},{"groupId":"OG001","value":"512","spread":null},{"groupId":"OG002","value":"2050","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"355","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"1677","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"383","spread":null},{"groupId":"OG002","value":"1543","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 6 Months to Less Than 36 Months.","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":null},{"groupId":"OG001","value":"31.3","spread":null},{"groupId":"OG002","value":"25.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"797","spread":null},{"groupId":"OG001","value":"645","spread":null},{"groupId":"OG002","value":"747","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.52","spread":null},{"groupId":"OG001","value":"10.1","spread":null},{"groupId":"OG002","value":"9.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"558","spread":null},{"groupId":"OG001","value":"583","spread":null},{"groupId":"OG002","value":"526","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.56","spread":null},{"groupId":"OG001","value":"6.62","spread":null},{"groupId":"OG002","value":"6.41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7","spread":null},{"groupId":"OG001","value":"12.0","spread":null},{"groupId":"OG002","value":"72.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.33","spread":null},{"groupId":"OG001","value":"5.26","spread":null},{"groupId":"OG002","value":"5.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.56","spread":null},{"groupId":"OG001","value":"32.9","spread":null},{"groupId":"OG002","value":"36.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines Without Corresponding B Strain in All Participants.","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.\n\nSeroconversion was defined as either a pre vaccination HAI titer \\<1:10 and a post vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a four-fold increase in post-vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"120","spread":null},{"groupId":"OG002","value":"1677","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"1543","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 6 Months to Less Than 36 Months.","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.\n\nSeroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"327","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"220","spread":null},{"groupId":"OG001","value":"237","spread":null},{"groupId":"OG002","value":"925","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null},{"groupId":"OG001","value":"242","spread":null},{"groupId":"OG002","value":"943","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"716","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"135","spread":null},{"groupId":"OG002","value":"550","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 3 Years to Less Than 9 Years.","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.\n\nSeroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"205","spread":null},{"groupId":"OG002","value":"832","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"353","spread":null},{"groupId":"OG001","value":"348","spread":null},{"groupId":"OG002","value":"1380","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"222","spread":null},{"groupId":"OG001","value":"212","spread":null},{"groupId":"OG002","value":"842","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"354","spread":null},{"groupId":"OG001","value":"351","spread":null},{"groupId":"OG002","value":"1383","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"263","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"1122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150","spread":null},{"groupId":"OG001","value":"281","spread":null},{"groupId":"OG002","value":"1124","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroprotection Against Influenza Vaccine Antigens After Vaccination With One Dose of Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.\n\nSeroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"289","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"139","spread":null},{"groupId":"OG002","value":"498","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"138","spread":null},{"groupId":"OG002","value":"504","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"341","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"350","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Seroprotection Against Influenza Vaccine Antigens After Vaccination With Two Doses of Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.\n\nSeroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"216","spread":null},{"groupId":"OG002","value":"870","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"462","spread":null},{"groupId":"OG001","value":"446","spread":null},{"groupId":"OG002","value":"1807","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"166","spread":null},{"groupId":"OG002","value":"687","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"465","spread":null},{"groupId":"OG001","value":"455","spread":null},{"groupId":"OG002","value":"1822","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"195","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"346","spread":null},{"groupId":"OG001","value":"147","spread":null},{"groupId":"OG002","value":"1497","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"141","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"318","spread":null},{"groupId":"OG002","value":"1324","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 3 Years to Less Than 9 Years.","description":"Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as \\<10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.5","spread":null},{"groupId":"OG001","value":"54.4","spread":null},{"groupId":"OG002","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1565","spread":null},{"groupId":"OG001","value":"1348","spread":null},{"groupId":"OG002","value":"1484","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.6","spread":null},{"groupId":"OG001","value":"64.1","spread":null},{"groupId":"OG002","value":"63.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"924","spread":null},{"groupId":"OG001","value":"1214","spread":null},{"groupId":"OG002","value":"1112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null},{"groupId":"OG001","value":"10.6","spread":null},{"groupId":"OG002","value":"9.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.09","spread":null},{"groupId":"OG001","value":"9.84","spread":null},{"groupId":"OG002","value":"9.34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null},{"groupId":"OG001","value":"86.9","spread":null},{"groupId":"OG002","value":"88.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Aged 6 Months to <36 Months Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines.","description":"Solicited injection site reactions (Age 6-23 Months): Tenderness, Erythema and Swelling. Solicited systemic reactions: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite, and Irritability.\n\nGrade 3: Tenderness: cries when injected limb is moved; Erythema and Swelling ≥ 50 mm; Fever: \\>103.1°F; Vomiting: ≥6 episodes/24 hours; Abnormal crying: \\>3 hours; Drowsiness: Sleeping most of the time; Loss of appetite: refuses ≥3 feeds/meals or most feeds/meals; Irritability: inconsolable.\n\nSolicited Injection site reactions (Age 24 Months to \\< 36 months): Pain, Erythema, and Swelling. Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.\n\nGrade 3: Pain: Incapacitating, unable to perform usual activities; Redness and Swelling: ≥ 50 mm; Fever: ≥102.1°F; Headache, Malaise and Myalgia: Significant, prevents daily activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"75","spread":null},{"groupId":"OG002","value":"297","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"340","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"429","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"248","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"164","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"259","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"46","spread":null},{"groupId":"OG002","value":"237","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"203","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"48","spread":null},{"groupId":"OG002","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"339","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Aged 3 Years to <9 Years Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines","description":"Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Fever (Temperature); Headache, Malaise and Myalgia Grade 3 Pain: incapacitating, unable to perform usual activities; Redness and Swelling: ≥ 50 mm; Fever: ≥ 102.1°F; Headache, Malaise and Myalgia: Significant, prevents daily activity, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":null},{"groupId":"OG001","value":"254","spread":null},{"groupId":"OG002","value":"1061","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"140","spread":null},{"groupId":"OG002","value":"543","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"103","spread":null},{"groupId":"OG002","value":"395","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"30","spread":null},{"groupId":"OG002","value":"112","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"97","spread":null},{"groupId":"OG002","value":"368","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"133","spread":null},{"groupId":"OG002","value":"508","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"153","spread":null},{"groupId":"OG002","value":"615","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"52","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":734},"commonTop":["Injection site pain","Injection site erythema","Myalgia","Malaise","Injection site Swelling"]}}}